Miromatrix to Report Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Miromatrix Medical Inc. (NASDAQ: MIRO) will report its financial results for the fourth quarter and full year 2021 on March 30, 2022, after market close. The company specializes in pioneering bioengineering technology for transplantable human organs, focusing primarily on livers and kidneys. Following the report, a conference call will take place at 3:30 PM CT, where management will discuss the results. Interested parties can join the call or listen to a live webcast through the company's investor relations webpage.

Positive

• Upcoming financial results announcement on March 30, 2022, indicating ongoing business transparency.
• Focus on innovative technology for bioengineering transplantable organs, addressing a critical healthcare need.

Negative

• None.

EDEN PRAIRIE, Minn., March 17, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, March 30, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. Please reference Conference ID: 13726822. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/.

About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
press@miromatrix.com

FAQ

When will Miromatrix report its 2021 financial results?

Miromatrix will report its financial results for the fourth quarter and full year 2021 on March 30, 2022.

What time is the Miromatrix conference call?

The conference call will begin at 3:30 PM Central Time on March 30, 2022.

How can I listen to the Miromatrix conference call?

You can listen to the Miromatrix conference call by calling 877-451-6152 for domestic calls or 201-389-0879 for international calls, or by visiting the investor relations section of their website.

What is the focus of Miromatrix's business?

Miromatrix focuses on bioengineering fully transplantable human organs, specifically livers and kidneys.